Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia

International Journal of Antimicrobial Agents

Volumn 38, Issue 3, 2011, Pages 231-236

  Jaruratanasirikul, Sutep ^a   Limapichat, Thanya ^a   Jullangkoon, Monchana ^a   Aeinlang, Nanchanit ^a   Ingviya, Natnicha ^a   Wongpoowarak, Wibul ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Lactam; Carbapenem; Pharmacokinetic pharmacodynamic

Indexed keywords

MEROPENEM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CROSSOVER PROCEDURE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; KLEBSIELLA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CRITICAL ILLNESS; ESCHERICHIA COLI; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; NEUTROPENIA; THIENAMYCINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051544312     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.04.019     Document Type: Article

References (37)

1. D. Nicolau, R. Quintiliani, and C.H. Nightingale Once-daily aminoglycosides Conn Med 56 1992 561 563 Erratum in: Conn Med 1992;56:694 (Pubitemid 23003752)
2. W.A. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 1995 89 96
3. B. Vogelman, S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W.A. Craig Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model J Infect Dis 158 1988 831 847
4. W.A. Craig, and S.C. Ebert Continuous infusion of β-lactam antibiotics Antimicrob Agents Chemother 36 1992 2577 2583
5. J. Lipman, C.D. Gomersall, T. Gin, G.M. Joynt, and R.J. Young Continuous infusion ceftazidime in intensive care: a randomized controlled trial J Antimicrob Chemother 43 1999 309 311 (Pubitemid 29082461)
6. J.W. Mouton, and J.G. den Hollander Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model Antimicrob Agents Chemother 38 1994 931 936 (Pubitemid 24150817)
7. L.R. Wiseman, A.J. Wagstaff, R.N. Brogden, and H.M. Bryson Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy Drugs 50 1995 73 101
8. E. Viaene, H. Chanteux, H. Servais, M.P. Mingeot-Leclercq, and P.M. Tulkens Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor operated syringes (intensive care units) Antimicrob Agents Chemother 46 2002 2327 2332 (Pubitemid 34793431)
9. P.K. Dandekar, D. Maglio, C.A. Sutherland, C.H. Nightingale, and D.P. Nicolau Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion Pharmacotherapy 23 2003 988 991 (Pubitemid 36903999)
10. J.L. Kuti, P.K. Dandekar, C.H. Nightingale, and D.P. Nicolau Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem J Clin Pharmacol 43 2003 1116 1123 (Pubitemid 37174443)
11. B.M. Lomaestro, and G.L. Drusano Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation Antimicrob Agents Chemother 49 2005 461 463 (Pubitemid 40065834)
12. S. Jaruratanasirikul, and S. Sriwiriyajan Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection J Antimicrob Chemother 52 2003 518 521 (Pubitemid 37120741)
13. S. Jaruratanasirikul, S. Sriwiriyajan, and J. Punyo Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection Antimicrob Agents Chemother 49 2005 1337 1339 (Pubitemid 40463358)
14. S. Jaruratanasirikul, N. Raungsri, J. Punyo, and S. Sriwiriyajan Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion J Antimicrob Chemother 56 2005 1163 1165 (Pubitemid 43009842)
15. S. Jaruratanasirikul, and T. Sudsai Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion J Antimicrob Chemother 63 2009 560 563
16. K. Ikawa, N. Morikawa, K. Ikeda, H. Ohge, and T. Sueda Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation Diagn Microbiol Infect Dis 62 2008 292 297
17. S.R. Norrby, K.L. Faulkner, and P.A. Newell Differentiating meropenem and imipenem/cilastatin Infect Dis Clin Pract 6 1997 291 303 (Pubitemid 27333302)
18. O. Lortholary, A. Lefort, M. Tod, A.M. Chomat, C. Darras-Joly, and C. Cordonnier Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia Lancet Infect Dis 8 2008 612 620
19. A. Nyhlén, B. Ljungberg, and I. Nilsson-Ehle Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish Study Group Eur J Clin Microbiol Infect Dis 16 1997 797 802 (Pubitemid 27527056)
20. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
21. Y. Ozkan, L. Kucukguzel, S.A. Ozkan, and H.Y. Aboul-Enein A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine Biomed Chromatogr 15 2001 263 266 (Pubitemid 32655143)
22. S. Jaruratanasirikul, and S. Sriwiriyajan Stability of meropenem in normal saline solution after storage at room temperature Southeast Asian J Trop Med Public Health 34 2003 627 629 (Pubitemid 38068080)
23. C.R. Wylie, and L.C. Barrett Advanced engineering mathematics 1982 McGraw-Hill Auckland, New Zealand
24. J. Li, and R.R. Rhinehart Heuristic random optimization Comput Chem Eng 22 1998 427 444 (Pubitemid 128644786)
25. N. Worakul, W. Wongpoowarak, and P. Boonme Optimization in development of acetaminophen syrup formulation Drug Dev Ind Pharm 28 2002 345 351 (Pubitemid 34475681)
26. C.D. Daykin, T. Pentikainen, and M. Pesonen Practical risk theory for actuaries 1994 Chapman and Hall London, UK
27. A.M. Ferrenberg, D.P. Landau, and Y.J. Wong Monte Carlo simulations: hidden errors from 'good' random number generators Phys Rev Lett 69 1992 3382 3384
28. W.A. Craig, and D. Andes Pharmacokinetics and pharmacodynamics of antibiotics in otitis media Pediatr Infect Dis J 15 1996 255 259 (Pubitemid 26098477)
29. G.L. Drusano Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 Suppl. 1 2003 S42 S50
30. V.H. Tam, P.S. Mckinnon, R.L. Akins, M.J. Rybak, and G.L. Drusano Pharmacodynamics of cefepime in patients with Gram-negative infections J Antimicrob Chemother 50 2002 425 428
31. W.A. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid Infect Dis Clin North Am 17 2003 479 501 (Pubitemid 38029149)
32. C. Li, J.L. Kuti, C.H. Nightingale, and D.P. Nicolau Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients J Clin Pharmacol 46 2006 1171 1178 (Pubitemid 44387417)
33. J.A. Roberts, C.M.J. Kirkpatrick, M.S. Roberts, T.A. Robertson, A.J. Dalley, and J. Lipman Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution J Antimicrob Chemother 64 2009 142 150
34. R.E. Ariano, A. Nyhlen, J.P. Donnelly, D.S. Sitar, G.K.M. Harding, and S.A. Zelenitsky Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia Ann Pharmacother 39 2005 32 38 (Pubitemid 40052375)
35. P.S. McKinnon, J.A. Paladino, and J.J. Schentag Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 2008 345 351
36. J.A. Roberts, C.M.J. Kirkpatrick, and J. Lipman Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients J Antimicrob Chemother 66 2011 227 231
37. J.H. Martin, M.F. Fay, A. Udy, J. Roberts, C. Kirkpatrick, and J. Ungerer Pitfalls of using estimations of glomerular filtration rate in an intensive care population Intern Med J 2010 10.1111/j.1445-5994.2010.02160.x